Aspire-Lakewood (ASBP) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aspire-Lakewood (ASBP) has outperformed Vistagen Therapeutics (VTGN) over the past year, losing 43.0% versus a loss of 93.9%. Aspire-Lakewood is the larger company by market cap ($11.6 million vs $10.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASBP | VTGN |
|---|---|---|
| Share price | $8.30 | $0.2462 |
| Market cap | $11.64M | $10.93M |
| 1-day change | -3.82% | -0.36% |
| YTD return | +57.20% | -62.70% |
| 1-year return | -42.99% | -93.88% |
| 5-year return | — | -99.66% |
| EPS (TTM) | $-30.89 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.76 | $5.14 |
| 52-week low | $0.11 | $0.20 |
| Distance from 52-week high | -55.76% | -95.21% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +306.17% |
| Average volume | 36.92K | 12.38M |
| Shares outstanding | 1.40M | 44.38M |
| Employees | — | 41 |
| Sector | Consumer Cyclical | Healthcare |
| Industry | Auto Parts | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASBP has outperformed VTGN by 50.9 percentage points over the past year.
- The two companies sit in different sectors: Aspire-Lakewood in Consumer Cyclical and Vistagen Therapeutics in Healthcare.
About Aspire-Lakewood
ASBP stock →Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.
Consumer Cyclical · Auto Parts
About Vistagen Therapeutics
VTGN stock →Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Healthcare · Biotechnology · 41 employees
ASBP vs VTGN FAQ
Which is bigger, Aspire-Lakewood or Vistagen Therapeutics?
Aspire-Lakewood (ASBP) is larger, with a market capitalization of $11.64M compared with $10.93M for Vistagen Therapeutics (VTGN).
Which stock has performed better over the past year, ASBP or VTGN?
ASBP returned -42.99% over the past 12 months, compared with -93.88% for VTGN (price return, excluding dividends). Past performance does not predict future results.
Are Aspire-Lakewood and Vistagen Therapeutics in the same industry?
No. Aspire-Lakewood is in the Consumer Cyclical sector, while Vistagen Therapeutics is in Healthcare.